- Guide to PHARMACOLOGY
Molecular properties generated using the CDK
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Guide to Malaria Pharmacology Comments|
|Halofantrine was developed by the Walter Reed Army Institute of Research and was a key compound identified during a antimalarial drug discovery programme that ran from 1963 until 1976 . The licensed drug was used in the treatment of both P. falciparum and P. vivax malaria but this has declined significantly due to potentially lethal cardiotoxic side effects and variable pharmacokinetic properties. It is not recommended for prophylactic use.
Potential Target/Mechanism Of Action: As the precise mechanism of action of halofantrine is not yet known, we do not have a molecular target for this compound. There is some evidence that suggests that halofantrine inhibits the haem detoxification pathway in the parasite, and that this action causes lethal haem toxicity [1,3].